Assistant Professor M.D. Office: 3005 CCRC Contact Phone Number: 542-6445 Lab: 3002 CCRC Lab Phone: 542-4683 E-mail: lwang@ccrc.uga.edu

Research Interests

Research in the Wang laboratory focuses on the structure and function of heparan sulfate in vasculature. Heparan sulfate is an abundant glycan found on the cell surface and in the extracellular matrix. In vitro studies have observed that heparan sulfate can interact with growth factors, growth factor binding proteins, extracellular proteases, protease inhibitors, chemokines, morphogens, and cell adhesive proteins to mediate cell differentiation, proliferation, migration, blood coagulation, lipid metabolism, and leukocyte trafficking. However, the relationship between heparan sulfates structure and function, and its molecular mechanism of action in vivo, are largely unknown. By using techniques, including conditional mouse gene targeting, embryonic stem (ES) cell differentiation, primary cell culture, and mouse models, the Wang lab is aiming to understand the roles and underlying molecular mechanisms of heparan sulfate in vascular development, inflammation, blood coagulation, and related diseases in vivo, and to develop novel approaches to cure the related pathological conditions.

Selected Recent Publications

• Borsig L*, Wang L*, Cavalcante MC, Cardilo-Reis L, Ferreira PL, Mourao PA Esko JD Pavao MS (2007) Selectin-blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea-cucumber: Effect on tumor metastasis and neutrophil recruitment. J Biol Chem. (*, co-first author) In press.
  
  
• Macarthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD (2007) Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 117(1):153-164.
  
  
• Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramaro P, Esko JD (2007) Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol 177:539-549.
  
  
• Wang LC, Fuster MM, Sriramarao P, Esko JD (2005). Endothelial deficiency of heparan sulfate impairs L-selectin and chemokine mediated neutrophil trafficking during inflammatory responses. Nat Immunol, 2005 Sep;6(9):902-10.
  
  
• Rele SM, Cui W, Wang LC, Hou S, Barr-Zarse G, Tatton D, Gnanou Y, Esko JD and Chaikof EL (2005). Dendrimer-like PEO glycopolymers exhibit anti-inflammatory properties. J Am Chem Soc 127(29):10132-3.
  
  
• Tang N, Wang LC, Esko JD, Giordano FJ, Huang Y, Gerber H, Ferrara N, Johnson RS (2004). Loss of HIF-1a in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-95.
  
  
• Bobardt MD, Salmon P, Wang LC, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA (2004). Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 78:6567-84.
  
  
• Fuster MM, Brown JR, Wang LC, and Esko JD (2003). A disaccharide precursor of sialyl Lewis X inhibits the metastatic potential of tumor cells. Cancer Res 63:2775-81.
  
  
• Wang LC, Brown JR, Varki A. and Esko JD (2002). Heparin`s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 110:127-36
  
  
• Harenberg J, Wang LC, Hoffmann U, Huhle G, Feuring M (2001). Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex. J Lab Clin Med 137:408-13.
  
  
• Harenberg J, Wang LC, Hoffmann U, Huhle G, Feuring M (2001). Improved laboratory confirmation of heparin-induced thormbocytopenia type II: Time course of antibodies and combination of antigen and biological assays. Am J Clin Pathol 115:432-8.
  
  
• Harenber J, Koch S, Giese C, Wang LC, Hoffmann U, Huhle G (2000). Quantitation of serotonin from platelets using enzyme-immunoassay in the presence of serum from HIT-patients. Thromb Haemost 83:795-6.
  
  
• Harenberg J, Huhle G ,Wang LC, Hoffmann U, Song XH and Heene DL (2000). Re-exposure to recombinant (r)-hirudin in antihirudin antibody positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 109:360-3.
  
  
• Song XH, Huhle G, Wang LC, Harenberg J (2000). Quantitative determination of PEG-hirudin in human plasma using a competitive enzyme linked immunosorbent assay. Thromb Res 99:195-202.
  
  
• Harenber J, Hoffmann U, Huhle G, Song XH, Wang LC (2000). Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin. Br J Haematol 108:528-30.
  
  
• Harenberg J, Huhle G, Hoffmann U, Wang LC. Diagnose und Therapie des HIT Typ II Syndroms. In: Modernes Thromboembolie-Management. Diagnostik-Prophylaxe-Therapie. Hrsg: Kiesewetter H, Koscielny J, Offermann M. Media Bibliothek. Pharmacia & Upjohn. 2000.
  
  
• Harenberg J, Giese Ch, Wang LC, Huhle G, Song XH, Hoffmann U, Heene DL (2000). Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 109:182-6.
  
  
• Marx A, Huhle G, Hoffmann U, Wang LC, Schuele B, Harenberg J (1999). Heparin-induced thrombocytopenia after elective hip replacement during prophylaxis of venous thromboembolism with low-molecular weight heparin. Z Orthop Ihre Grenzgeb 137:536-9.
  
  
• Huhle G, Hoffmann U, Song XH, Wang LC, Heene DL, Harenberg J (1999). Immunological response to recombinant hirudin in heparin-induced thrombocytopenia type II patients during long-term treatment. Br J Haematol 106: 195-201.
  
  
• Song XH, Huhle G,Wang LC, Hoffmann U, Harenberg J (1999). Generation of anti-hirudin antibodies in heparin-induced thrombocytopenia patients treated with r-hirudin. Circulation 101:1528-32.
  
  
• Harenberg J, Huhle G, Wang LC, Hoffmann U, Bayerl Ch, Kerowgan M (1999). Association of heparin-induced skin lesions, intracutaneous tests and heparin-induced IgG. Allergy 54:473-7.
  
  
• Hoffmann U, Huhle G, Wang LC, Song XH and Harenberg J. Messung von Heparin-induzierten IgG-Antik rpern mittels >> fluorescence-Linked Immunofiltration Assay<< (FLIFA) bei Heparin-induzierter Thrombozytopenie Typ II (1999). H mostaseologie 19:13-8.
  
  
• Wang LC, Huhle G, Malsch R, Hoffmann U, Song XH and Harenberg J (1999). Determination of heparin-induced IgG in heparin-induced thrombocytopenia type II patients. Eur J Clin Invest 29:232-7.
  
  
• Wang LC, Huhle G, Malsch R, Hoffmann U, Song XH and Harenberg J (1999). Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). J Immunol Methods 222:93-9.
  
  
• Wang LC, Huhle G, Hoffmann U, Song XH and Harenberg J (1998). Heparin-induced thrombocytopenia: New methods for determination, diagnosis and inside into pathophysiology. Clin Lab 44:771-80.
  
  
• Harenberg J, Huhle G, Piazolo L, Wang LC and Heene DL (1997). Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thrombo Hemostas 23:189-96.
  
  
• Wang LC, Malsch R and Harenberg J (1997). Heparins, Low-molecular-weight heparins, and other glycosaminoglycans analyzed by agarose gel electrophoresis and azure A - silver staining. Semin Thrombo Hemostas 23(1):11-6.
  
  
• Wang LC, He SL and Chen ZY (1995). Purification of histidine-rich glycoprotein and its procoagulant activity. Bull Hunan Med Univ 21(4):315-8.
  
  
• Zeng WM, Wang LC, Chen ZY, Yan RC, Tan MX and Hu XP (1994). Preliminary study on determination of serum glycated proteins using glucose phenylosazone spectrophotometric assay. Bull Hunan Med Univ 19(6):491-4.